Bebt-109
EGFR Exon 20 Insertion Mutation
BeBetter Med IncPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the EGFR Exon 20 Insertion Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Blueprint Medicines Corporation | Phase 1 | CC |
Pebezertinib Blueprint Medicines Corporation | Phase 1 | CC |
Tarloxotinib Rain Oncology Inc | Phase 2 | D |
Same molecule, other indications
Bebt-109 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →